Among breast cancer subtypes, triple-negative breast cancer (TNBC) poses significant challenges due to the absence of expression (or minimal expression) of estrogen receptor (ER) and progesterone receptor (PR) as well as an absence of human epidermal growth factor receptor-2 (HER2) overexpression, limiting treatment options to non-targeted chemotherapy. Here, PGR is linked to triple-negative breast carcinoma.